Skip to main content

Advertisement

SpringerLink
Log in

Interleukin-10 and Interleukin-10–Receptor Defects in Inflammatory Bowel Disease

  • Immune Deficiency and Dysregulation (DP Huston, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease characterized by abdominal pain, bloody diarrhoea, and malabsorption leading to weight loss. It is considered the result of inadequate control of an excessive reaction of the immune system to the resident flora of the gut. Like other primary immunodeficiencies, IL-10 and IL-10 receptor (IL10R) deficiency present with IBD and demonstrate the sensitivity of the intestine to any changes of the immune system. Both IL-10 and IL10R deficiency cause severe early-onset enterocolitis and can be successfully treated by hematopoietic stem cell transplantation (HSCT).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29.

    Article  PubMed  CAS  Google Scholar 

  2. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995–1000.

    Article  PubMed  CAS  Google Scholar 

  3. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–34.

    Article  PubMed  CAS  Google Scholar 

  4. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571–83.

    Article  PubMed  CAS  Google Scholar 

  5. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present, and future: lessons from animal models. J Gastroenterol. 2008;43:1–17.

    Article  PubMed  Google Scholar 

  6. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206:60–76.

    Article  Google Scholar 

  7. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.

    Article  PubMed  CAS  Google Scholar 

  8. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet. 2009;10:89–116.

    Article  PubMed  Google Scholar 

  9. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol. 2010;10:182–92.

    Article  PubMed  CAS  Google Scholar 

  10. Cheng LE, Kanwar B, Tcheurekdjian H, Grenert JP, Muskat M, Heyman MB, et al. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol. 2009;132:124–31.

    Article  PubMed  CAS  Google Scholar 

  11. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol. 2009;104:117–24.

    Article  PubMed  CAS  Google Scholar 

  12. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116:1079–82.

    Article  PubMed  CAS  Google Scholar 

  13. Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) vs type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.

    Article  PubMed  Google Scholar 

  14. Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol. 2008;28 Suppl 1:S11–9.

    Article  PubMed  CAS  Google Scholar 

  15. • Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the Interleukin-10 Receptor. N Engl J Med. 2009;361:2033–45. First report on IL10R deficient patients and therapy by HSCT.

    Article  PubMed  CAS  Google Scholar 

  16. • Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, et al. Infant colitis – it’s in the genes. Lancet. 2010;376:1272. First report on patients with early-onset IBD and mutant IL-10.

    Article  PubMed  Google Scholar 

  17. • Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, et al. Defective IL-10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011;106:1544–55. Demonstrates impaired IL22 signaling in intestinal tissue samples of a patient with IL10R2 deficiency.

    Article  PubMed  CAS  Google Scholar 

  18. • Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease - implications for diagnosis and therapy. Gastroenterology. 2012;143:347–55. Most recent study on IL-10/IL10R deficiency and curative therapy using HSCT.

  19. • Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, et al. IL10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2012. doi:10.1002/ibd.22974. First identification of a splice site mutation in IL10R1 resulting in infantile onset IBD.

  20. • Mao H, Yang W, Lee PP, Ho MH, Yang J, Zeng S, et al. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. Genes Immun. 2012;13:437–42. First description of a compound heterozygous mutation causing IL10R deficiency and IBD.

  21. • Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011;365:1502–8. Most recent genetic defect associated with IBD and skin disease.

    Article  PubMed  CAS  Google Scholar 

  22. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2:1366–9.

    Article  PubMed  CAS  Google Scholar 

  23. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Inborn errors working party of the European group for blood and marrow transplantation; european society for immunodeficiency. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10.

    Article  PubMed  Google Scholar 

  24. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ. Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr. 2005;40:582–8.

    Article  PubMed  Google Scholar 

  25. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991;174:1549–55.

    Article  PubMed  CAS  Google Scholar 

  26. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187:571–8.

    Article  PubMed  CAS  Google Scholar 

  27. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263–74.

    Article  PubMed  Google Scholar 

  28. Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995;96:2339–47.

    Article  PubMed  CAS  Google Scholar 

  29. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.

    Article  PubMed  CAS  Google Scholar 

  30. Barnes M, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31:401–11.

    Article  PubMed  CAS  Google Scholar 

  31. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol. 2003;15:430–5.

    Article  PubMed  CAS  Google Scholar 

  32. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL-10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319–23.

    Article  PubMed  CAS  Google Scholar 

  33. Amre DK, Mack DR, Morgan K, Israel D, Lambrette P, Costea I, et al. Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn's disease. Aliment Pharmacol Ther. 2009;29:1025–31.

    Article  PubMed  CAS  Google Scholar 

  34. Noguchi E, Homma Y, Kang X, Netea MG, Ma X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL-10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10:471–9.

    Article  PubMed  CAS  Google Scholar 

  35. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008;121:1108–11.

    Article  PubMed  CAS  Google Scholar 

  36. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.

    Article  PubMed  CAS  Google Scholar 

  37. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2(IL10R2) chain. J Leukoc Biol. 2004;76:314–21.

    Article  PubMed  CAS  Google Scholar 

  38. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.

    Article  PubMed  CAS  Google Scholar 

  39. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309–23.

    Article  PubMed  CAS  Google Scholar 

  40. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–44.

    PubMed  CAS  Google Scholar 

  41. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008;29:947–57.

    Article  PubMed  CAS  Google Scholar 

  42. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–9.

    Article  PubMed  CAS  Google Scholar 

  43. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med. 2008;14:275–81.

    Article  PubMed  CAS  Google Scholar 

  44. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.

    Article  PubMed  CAS  Google Scholar 

  45. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.

    Article  PubMed  CAS  Google Scholar 

  46. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.

    Article  PubMed  CAS  Google Scholar 

  47. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995;108:1434–44.

    Article  PubMed  CAS  Google Scholar 

  48. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461–72.

    Article  PubMed  CAS  Google Scholar 

  49. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473–82.

    Article  PubMed  CAS  Google Scholar 

  50. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50:191–5.

    Article  PubMed  CAS  Google Scholar 

  51. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383–9.

    Article  PubMed  Google Scholar 

  52. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–5.

    Article  PubMed  CAS  Google Scholar 

  53. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754–9.

    Article  PubMed  CAS  Google Scholar 

  54. Nakase H, Okazaki K, Tabata Y, Ozeki M, Watanabe N, Ohana M, et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2002;301:59–65.

    Article  PubMed  CAS  Google Scholar 

  55. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut. 2003;52:981–7.

    Article  PubMed  CAS  Google Scholar 

  56. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut. 2000;46:344–9.

    Article  PubMed  CAS  Google Scholar 

  57. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200–9.

    Article  PubMed  CAS  Google Scholar 

  58. Van Montfrans C, Rodriguez Pena MS, Pronk I, Ten Kate FJ, Te Te Velde AA, Van Deventer SJ. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002;123:1865–76.

    Article  PubMed  Google Scholar 

  59. McCarthy BA, Reddi AS, Coakley KM, Nguyen SM, Nayal RR, Javdan M, et al. Administration of human umbilical cord blood cells produces interleukin-10 (IL-10) in IL-10 deficient mice without immunosuppression. Curr Stem Cell Res Ther. 2010;5:13–6.

    Article  PubMed  CAS  Google Scholar 

  60. Bamba S, Lee CY, Brittan M, Preston SL, Direkze NC, Poulsom R, et al. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J Pathol. 2006;209:265–73.

    Article  PubMed  CAS  Google Scholar 

  61. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res. 1999;19:563–73.

    Article  PubMed  CAS  Google Scholar 

  62. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178:2623–9.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

Dr. Glocker has received grant support from the European Commission. Drs. Shah, Kammermeier, and Elawad reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Department of Paediatric Gastroenterology, Great Ormond Street Hospital, University College London, London, UK

    Neil Shah, Jochen Kammermeier & Mamoun Elawad

  2. Institute of Medical Microbiology and Hygiene, University Hospital Freiburg, Hermann-Herder-Str. 11, 79104, Freiburg, Germany

    Erik-Oliver Glocker

Authors
  1. Neil Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jochen Kammermeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamoun Elawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erik-Oliver Glocker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erik-Oliver Glocker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, N., Kammermeier, J., Elawad, M. et al. Interleukin-10 and Interleukin-10–Receptor Defects in Inflammatory Bowel Disease. Curr Allergy Asthma Rep 12, 373–379 (2012). https://doi.org/10.1007/s11882-012-0286-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-012-0286-z

Keywords

Search

Navigation